GS
XERS icon

George Soros’s Xeris Biopharma Holdings XERS Stock Holding History

George Soros’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,248
Closed -$25K – 171
2020
Q3 		$25K Sell
4,248
-195,752
-98% -$783K ﹤0.01% 132
2020
Q2 		$532K Buy
+200,000
New +$696K 0.01% 132

Other funds holding XERS

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

George Soros's XERS Position: Q4 2020 in Review

George Soros sold out of Xeris Biopharma Holdings (XERS) in Q4 2020, closing a stake of 4,248 shares — an estimated $25K sold.

George Soros first reported a position in XERS in Q2 2020 and held it in 2 quarters. The position peaked at $532K in Q2 2020. 96 funds tracked by Wall St. Rank hold XERS as of Q4 2020.

  • George Soros reported no remaining Xeris Biopharma Holdings position as of Q4 2020 after selling out during the quarter.
  • George Soros sold 4,248 Xeris Biopharma Holdings shares in Q4 2020, an estimated $25K.
  • George Soros first reported a position in Xeris Biopharma Holdings in Q2 2020 and held it in 2 quarters.
  • George Soros's Xeris Biopharma Holdings position peaked at $532K in Q2 2020.
  • 96 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2020.

Based on Soros Fund Management's 13F filing for Q4 2020, filed 16 Feb 2021.